Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + trametinib + venetoclax
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
azacitidine + trametinib + venetoclax is a combination therapy regimen being investigated at the University of Texas M.D. Anderson Cancer Center. It consists of the oral MEK inhibitor trametinib, the hypomethylating agent azacitidine, and the BCL-2 inhibitor venetoclax. This triplet regimen is specifically designed to treat patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML), who harbor RAS pathway-activating mutations. By simultaneously inhibiting the MAPK/ERK signaling pathway (via trametinib), blocking the anti-apoptotic protein BCL-2 (via venetoclax), and inducing DNA hypomethylation (via azacitidine), the therapy aims to overcome resistance mechanisms commonly seen in RAS-mutated myeloid cancers.
- Other names
- Trametinib with Azacitidine and VenetoclaxAzacitidine, Venetoclax and Trametinib
02
Targets
MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on azacitidine + trametinib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + trametinib + venetoclax.